Statements (36)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
fibrate |
| gptkbp:approvalYear |
1982
|
| gptkbp:ATCCode |
C10AB04
|
| gptkbp:bioavailability |
well absorbed
|
| gptkbp:brand |
gptkb:Lopid
|
| gptkbp:CASNumber |
25812-30-0
|
| gptkbp:contraindication |
severe liver disease
gallbladder disease |
| gptkbp:discoveredBy |
gptkb:Parke-Davis
|
| gptkbp:drugInteraction |
gptkb:warfarin
statins |
| gptkbp:eliminationHalfLife |
1.5 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:hasMolecularFormula |
C15H22O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
gemfibrozil
|
| gptkbp:KEGGID |
gptkb:D00351
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
PPARĪ± agonist
|
| gptkbp:MeSH_ID |
D005783
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
3345
3465 CHEMBL1091 DB01241 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
muscle pain
gastrointestinal upset liver dysfunction |
| gptkbp:UNII |
JL5DK93RCL
|
| gptkbp:usedFor |
hyperlipidemia
hypertriglyceridemia |
| gptkbp:bfsParent |
gptkb:Vytorin
gptkb:Imodium |
| gptkbp:bfsLayer |
5
|